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Evolving literature suggests that the epidemic of prescription opioid use affects the transplant population. 
We examined a novel database wherein national U.S. transplant registry records were linked to a large 
pharmaceutical claims warehouse (2007 to 2015) to characterize prescription opioid use before and after 
kidney transplant, and associations (adjusted hazard ratio, 95% LCLaHR95% UCL) with death and graft loss. 
Among 75,430 eligible patients, 43.1% filled opioids in the year before transplant. Use was more common 
among recipients who were women, white, unemployed, publicly insured, and with longer pre-transplant 
dialysis. Of those with the highest level of pre-transplant opioid use, 60% continued high-level use post-
transplant. Pre-transplant opioid use had graded associations with 1-year post-transplant outcomes; the 
highest-level use predicted 46% increased risk of death (aHR 1.281.461.66) and 28% increased risk of all-
cause graft failure (aHR 1.171.281.41). Effects of high-level opioid use in the first year after transplant were 
stronger, predicting twice the risk of death (aHR 1.932.242.60) and 68% higher all-cause graft loss risk (aHR 
1.501.681.89) over the subsequent year; increased risk persisted over 5 years. While associations may, in 
part, reflect underlying conditions or behaviors, opioid use history is relevant in assessing and providing 




















Candidates for transplant undergo evaluation of the severity of end-stage organ failure, comorbid 
conditions, overall fitness for surgery, and psychosocial status including risk factors for poor adherence 
after transplant.(1, 2) Similarly, living donor candidates are carefully evaluated for medical and 
psychosocial suitability for donation.(3) Medication therapies are reviewed to assess treatment 
appropriateness and identify possible drug interactions that might occur after surgery. However, while 
substantial attention is invested in the evaluation clinic to identify traditional risk factors, we often 
overlook medications that might be markers for serious conditions, lack of adherence, or other behaviors 
that may affect patient and allograft survival. Until recently, use of pharmaceutical claims to 
quantitatively inform expectations for clinical outcomes before and after transplant and living organ 
donation has not been described. 
Opioid analgesics serve an important role in management of acute and chronic pain, but 
reIogﾐitioﾐ of aﾐ さepideﾏiIざ of IoﾏpliIatioﾐs related to the over-prescribing, misuse, and inherent 
potential toxicity of prescription opioids is growing.(4, 5) The daily news resounds with descriptions of this 
epidemic and the national surge in opioid-related deaths.(6-8) Pre-surgical use of opioid analgesics is 
increasingly recognized as a predictor of post-operative complications and resource utilization in diverse 
populations, including those undergoing general, orthopedic, and liver transplant surgeries, as well as 
living donor nephrectomy procedures (9-12).  Concerns about opioid-related toxicity are even greater in 
patients with end-stage organ failure due to altered drug protein binding, metabolism, and excretion, 
leading to accumulation of parent agents and potentially toxic metabolites.(13, 14) Patients who use high 
levels of opioids may also have increased risk of nonadherence to prescribed care. 
Recently, we developed a novel integrated database incorporating dispensed prescription records 
from a large pharmaceutical claims warehouse with the national transplant registry data. Using these 
linked data, we identified adverse clinical outcomes in transplant recipients who filled prescription opioids 
before surgery, including increased risk of death and graft failure after liver transplant,(11) and increased 
risk of readmission after living donor nephrectomy.(12) Among samples of kidney transplant recipients, 
2005-2010, we found that compared with those who did not fill opioids, patients with the highest level of 
pre-transplant opioid use had a 63% increased risk of death and a 41% increased risk of all-cause graft 
failure,(15) and increased risks of posttransplant complications, such as cardiovascular, respiratory, or 
neurological events.(16) These findings resonate with a new report of graded increases in death rates 


















To address the effect of AﾏeriIa’s opioid epideﾏiI on kidney transplant recipients, we extended 
our previous work examining associations between pre-transplant opioid use and transplant outcomes by 
studying a larger, more contemporary cohort of recipients who underwent kidney transplant through 
2015. In addition, we examined relationships of pre-transplant opioid use with opioid fills in the year after 
transplant, and associations of post-transplant use with subsequent outcomes. We hypothesized that pre- 
and post-transplant prescription opioid use are associated with patient and graft outcomes after kidney 




We conducted a retrospective cohort study using linked healthcare databases in the U.S. to ascertain 
patient characteristics, pharmacy fill records, and outcome events for kidney transplant recipients. This 
study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR system includes 
data on all donors, waitlist candidates, and transplant recipients in the U.S., submitted by the members of 
the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services 
Administration (HRSA), U.S. Department of Health and Human Services, provides oversight to the 
activities of the OPTN and SRTR contractors.  
Pharmacy fill data were assembled by linking SRTR records for kidney transplant recipients with 
billing claims from Symphony Health Solutions (SHS), a large U.S. pharmaceutical claims data warehouse 
that collects prescription drug fill records including self-paid fills and those reimbursed by private and 
public payers. SHS comprises National Council for Prescription Drug Program format prescription claims 
aggregated from multiple sources including claims warehouses, retail pharmacies, and prescription 
benefit managers for approximately 60% of U.S. retail pharmacy transactions. Individual claim records 
include the date of a given pharmacy fill with the national drug code identifying agent and dosage. After 
Institutional Review Board and HRSA approvals, SHS records were linked with SRTR records for kidney 
transplant recipients. We applied a deterministic de-identification strategy wherein patient identifiers 
(last name, first name, date of birth, sex, and ZIP code of residence) were transformed before delivery to 
the Saint Louis University researchers with Health Information Portability and Accountability Act and 
HITECH-certified encryption technology from SHS. The patient de-identification software employs multiple 
eﾐIryptioﾐ algorithﾏs iﾐ suIIessioﾐ to guaraﾐtee that the resultiﾐg さtokeﾐざ Ioﾐtaiﾐiﾐg eﾐIrypted patieﾐt 
identifiers can never be decrypted. However, the algorithm yields the same results for a given set of data 


















All direct identifiers were removed before the final dataset was available for analysis. Because of 
the large sample size, the anonymity of the patients studied, and the non-intrusive nature of the research, 
a waiver of informed consent was granted per the Department of Health and Human Services Code of 
Federal Regulations (Title 45, Part 46, Paragraph 46.116).  
Population and Covariates 
We included kidney transplant recipients who underwent transplant between 2007 and 2015 and who 
had 1 year of pretransplant pharmacy fill records in SHS. We examined a subgroup of the cohort with 
available data in the records to ascertain prescription opioid use in the 1 year before and after transplant. 
Transplant recipient clinical and demographic characteristics, and characteristics of the donated organ 
and other transplant factors, were defined by the OPTN Transplant Candidate Registration and Transplant 
Recipient Registration forms (Table 1). 
 Pharmacy fills for opioid analgesics in the 1 year before and after transplant were ascertained 
from the SHS records. Opioid use was normalized to morphine equivalents (ME), according to conversion 
ratios, as previously described (Table S1).(7,8) Pre- and post-transplant ME were aggregated, separately 
within each period, for each recipient and expressed as dose (mg) of ME exposure over the year. We 
ranked annual ME exposure among recipients who filled opioid prescriptions by levels as: level 1, 300 
mg; level 2, 301-600 mg; level 3, 601-1000 mg; and level 4, >1000 mg per year, similar to previous 
methods.(11, 12, 15, 16) We performed sensitivity analyses considering opioid filling patterns within 6 
months and in months 7 to 12 prior to transplant. 
 
Outcome Measurements 
The primary outcomes were all-cause mortality and graft failure. Graft failure was defined as return to 
maintenance dialysis or re-transplant. All-cause graft failure included graft loss due to patient death. In 
the analysis of pre-transplant opioid use, outcomes were assessed at the 1-year posttransplant date. In 
the analysis of post-transplant opioid use, outcomes were assessed between the 1- and 2-year 
posttransplant dates. Observation time was censored at the end of follow-up (December 31, 2016). 
 
Statistical Analyses 
Datasets were merged and analyzed with SAS (Statistical Analysis Software) version 9.4 (SAS Institute Inc., 
Cary, NC). Distributions of clinical and demographic traits among recipients with each level of pre-
transplant opioid exposure, compared with no opioid use, were compared by Chi-square test. Propensity 


















were constructed by multivariate logistic regression. Adjusted associations of pre- and posttransplant 
opioid use with posttransplant death and graft failure (adjusted hazard ratio with 95% upper and lower 
confidence limits, LCLaHRUCL) were quantified by multivariate Cox regression including adjustment for 
recipient, donor, and transplant clinical factors. In all outcome analyses, we interpreted two-tailed p-
values <0.05 as statistically significant.  
 
RESULTS 
Baseline Characteristics of Kidney Transplant Recipients 
A STROBE checklist for the study is provided in Table S1. Between 2007 and 2015, 117,931 adult kidney 
transplant recipients in the U.S. were recorded in the SRTR database. Of these, 75,430 (64.0%) also had 
available pre-transplant medication data in SHS (Table 1) and 76,187 (64.6%) had available posttransplant 
medication data in SHS (Table S3). In the study sample with available pretransplant medication data, 
mean age at the time of transplant was 49.8 years (standard deviation, 15.8 years); 39.3% were female, 
53.1% were white, and 26.7% were African American. In the study sample, 32,483 recipients (43.1%) filled 
≥ヱ opioid prescription in the year before transplant. Compared with recipients who did not use opioids 
before transplant, those with the highest level of use (level 4) were more often aged 45-59 years, women, 
of white race, unemployed, publicly insured, and less likely to be college educated (Table 1). Recipients 
with level 4 pre-transplant opioid use were also more likely to be obese (body mass index >30 kg/m
2
), and 
to have comorbid conditions (diabetes mellitus, coronary artery disease, cerebral vascular disease, 
peripheral vascular disease, chronic obstructive pulmonary disease), longer pre-transplant dialysis 
duration, and higher rates of sensitization. 
 
Death and Graft Failure According to Pre-transplant Opioid Use Level 
Overall, 2.5% of recipients died within the first year post-transplant. Incidence of 1-year death-censored 
graft failure and all-cause graft failure were 3.0% and 3.2%, respectively, occurring at median times from 
transplant of 54 and 62 days, respectively. Compared with recipients with no pre-transplant opioid use, 
those with level 4 use had an increased risk of death (3.9% vs. 2.5%, p<0.0001), death-censored graft 
failure (3.9% vs. 3.1%, p=0.0002), and all-cause graft loss (7.2% vs. 5.1%, p<0.0001) (Figure 1). After 
adjustment for demographic, clinical, and procedure factors, level 4 pre-transplant opioid use was 
associated with a 46% increased risk of death within the first year posttransplant (aHR 1.281.461.66, 
p<0.0001), and with an increased risk of death-censored graft failure (aHR 1.011.151.30, p=0.031) and all-


















terms of fills within >0-6 months and 7-12 months before transplant, we also observed graded increased 
in the risks of death and graft loss with higher-level opioid use in either period, although risk is greatest 
with the combination of high-level use in both periods (Figure S1). For example, level 4 use in both pre-
transplant periods was associated with 78% higher risk of death (aHR 1.611.781.96) and 51% higher risk of 
all-cause graft failure (aHR 1.341.511.69) in the year after transplant. 
 
Patterns of Opioid Use Before and After Transplant 
We examined a subgroup of the cohort (n=58,154, 77.1%) with available data in the pharmacy records to 
determine prescription opioid use in the 1 year before and after transplant. Overall, 70.5% of recipients 
who filled an opioid prescription in the 1 year before transplant continued to fill opioid prescriptions in 
the 1 year after transplant. Recipients with higher levels of post-transplant opioid use were more likely to 
show higher levels of pre-transplant opioid use (Figure 3). Almost 60% of level 4 opioid users pre-
transplant continued high level use posttransplant. Clinical correlates of posttransplant opioid use 
included factors associated with pre-transplant opioid use, such as female sex, African American race, less 
than college education, unemployment, obesity, and physical limitations (Table S4). Age 31-44 years was 
also associated with posttransplant opioid use. 
 
Death and Graft Failure According to Post-transplant Opioid Use Level 
Overall, 1.5% of recipients died in the first or second post-transplant year. During that time, incidence of 
death-censored graft failure was 1.7% and of all-cause graft failure 3.1%. Compared with non-users, 
recipients with level 2-4 opioid use in the first posttransplant year had an increased risk of death, death-
censored graft failure, and all-cause graft failure (Figure 1). After adjustment for demographic, clinical, 
and procedure factors, level 4 post-transplant opioid use was associated with a 2-fold increased risk of 
death over the next post-transplant year (aHR 1.932.242.60, p<0.0001), 35% increased risk of death-
censored graft failure (aHR 1.151.351.59, p=0.0003) and 68% increased risk of all-cause graft failure (aHR 
1.501.68 1.89, p<0.0001) compared with no use (Table 3, Figure 2). Risk relationships persisted with 
extension of observation time over five years after the first anniversary (Figure S2). For example, level 4 
post-transplant opioid use was associated with a 67% increased risk of death (aHR 1.551.671.80, p<0.0001), 
13% increased risk of death-censored graft failure (aHR 1.031.131.24, p=0.008), and 39% increased risk of all-
cause graft failure (aHR 1.311.39 1.48, p<0.0001) compared with no use. 







































The national epidemic of prescription opioid use is affecting patients across domains of care. Because of 
high-frequency use and potential for increased risks due to altered drug metabolism, prescription opioids 
are a particular concern among populations with end-stage organ failure, including transplant recipients. 
We examined prescription opioid fills among a contemporary sample of 75,000 kidney transplant 
recipients and observed several key findings: 1) Consistent with a prior report, pre-transplant prescription 
opioid use was associated with an approximately 45% increased risk of death and a 28% increased risk of 
all-cause graft failure over the first year posttransplant. 2) Most (70.5%) recipients who filled an opioid 
prescription in the year preceding transplant continue opioid use in the year after, and most high-level 
opioid users continued to fill at high levels. 3) Post-transplant prescription opioid use in the first year had 
ever stronger prognostic significance, predicting a 2-fold increased risk of death and a 68% increased risk 
of all-cause graft failure over the subsequent year. Increased risk persisted over five years of observation.  
 In this larger cohort of recipients including 5 years of more recent data, we confirmed our 
previous findings that high-level prescription opioid use in the year preceding kidney transplant was 
associated with increased risk of death and graft loss.(15) These findings are consistent with a 
retrospective study at a Midwest U.S. center by Barrantes et al.: kidney transplant recipients’ self-
reported long-term opioid use before transplant was associated with a 2-fold higher risk of death but 
similar risk of graft loss; graft loss risk was not based on self-reported medication use but identified 
through chart review.(18) The kidney transplant evaluation period is an opportunity for the transplant 
teaﾏ to re┗ie┘ the Iaﾐdidate’s comorbid conditions and medication list to assess risks, and counsel and 
optimize care before surgery. Pretransplant opioid use may become more prevalent, since end-stage 
renal disease (ESRD) patients have multiple potential sources of acute and chronic pain, including 
underlying causes of ESRD (e.g., polycystic kidney disease), other comorbidity (e.g., diabetes mellitus), 
renal complications (e.g., calciphylaxis), and vascular access complications (e.g., steal syndrome with 
arteriovenous fistulas).(19-23) One Canadian survey of 205 hemodialysis patients reported that 50% were 
affected by pain, of which 83% reported moderate-severe pain.(22) A new study of prescription fills 
among Medicare-insured dialysis patients found that overall, more than 60% filled at least one opioid 
prescription every year.(17) Our results support the notion that pretransplant prescription opioid use is 
not only prevalent in this unique patient population, but it also has implications for posttransplant patient 
and graft survival.  
 Patients who used prescription opioids pre-transplant were likely to continue use posttransplant. 
In our current study, 60% of recipients with the highest level of pre-transplant prescription opioid use 


















due to persistent pain. In a cross-sectional study of 164 hemodialysis patients and 114 stable deceased 
donor kidney transplant recipients, prevalence of reported pain was similar (63% vs. 62%), suggesting that 
successful kidney transplant does not reduce the prevalence of chronic pain in patients with ESRD.(24) 
Similarly, at one U.S. center, pre-transplant opioid use was the strongest predictor of posttransplant 
use.(25) Due to the nature of our available data sources, we were unable to determine the reason for 
ongoing prescription opioid use. Thus, it is unknown whether kidney transplant recipients experience 
persistent pain posttransplant requiring opioid treatment, or whether pain management was not 
reassessed posttransplant and the pre-transplant regimen was continued. While the former may 
represent appropriate management, efforts should be made to prevent the latter and to review and 
attempt to wean opioids that are no longer needed.  
 In our study, prescription opioid use in the first year after transplant had a strong, graded 
associated with increased risk of death and graft loss in the subsequent year, and the highest level of use 
predicted 2-fold increased risk of death, 35% increased risk of death-censored graft failure, and 68% 
increased risk of all-cause graft failure compared with non-use. Poorer outcomes with opioid use in kidney 
transplant recipients may reflect comorbidity associated with chronic pain, such as diabetes mellitus, or 
psychiatric conditions such as depression.(26) In addition, opioid use may be related to riskier patient 
behaviors, such as non-compliance with appointments or immunosuppressive medications, which may 
increase the risk of adverse posttransplant outcomes.(27) At one center, Kulshrestha et al found that 
opioid use in the first year was associated with increased readmission rates but no difference in rejection 
rates.(25) Further research is needed to understand the factors contributing to the increased risk of death 
and graft failure in kidney transplant recipients who require opioids for ongoing pain management. 
Regardless of the mechanisms of association, identification of novel markers of post-transplant 
outcomes is timely and can help transplant programs assess and manage risk at a programmatic level. 
Transplantation in the US is an increasingly regulated field with a high level of public reporting. Transplant 
centers are graded for recipient and graft survival using risk-adjusted equations developed by SRTR to 
predict expected 1-year post-transplant patient and graft survival.(28) Importantly, SRTR equations do not 
adjust for pain or medication use history as risk factors for post-transplant death or graft loss. Thus, 
centers performing transplants in patients who require prescription opioids before and after transplant 
should be aware of un-identified risk that will not be recognized by SRTR, and should consider extra 
monitoring and focused post-transplant care of these recipients. 
 Our study has a number of strengths, including use of a novel integrated national data registry 
that allows identification of prescription opioid fills. Electronic prescription fills have been shown to be 


















questionnaires.(29, 30) We used these data to understand the implications of pre- and post-transplant 
prescription opioid use for clinically relevant outcomes in a large cohort of kidney transplant recipients. 
We were also able to describe patterns of opioid use among recipients before and after transplant.  
 There are limitations to our study. We describe associations but are unable to prove causation 
between opioid use and adverse clinical outcomes. While use of pharmacy electronic records to identify 
prescription fills may be more accurate than self-report, opioid use and its impact may be underestimated 
as we were unable to account for illicit drug use, さpharﾏaIy shoppiﾐgざ Heha┗iors, or prescription fills at 
pharmacies not included in SHS. However, these patients would likely still be categorized as high-level 
users if they filled their opioid prescriptions at the same pharmacy as their immunosuppressive 
prescriptions. In addition, unmeasured confounders may have affected our findings, resulting in 
uncontrolled confounding by indication. We lacked information on laboratory values and transplant 
kidney biopsy pathology results. We were also unable to accurately identify patients who may have drug 
dependency or addiction issues, and we lacked data on patient compliance. Lastly, as noted, we were 
unable to determine whether opioid use pre- and post-transplant is continually monitored and managed 
for appropriateness.  
 In conclusion, our results reinforce growing concern about the outcome implications of 
prescription opioids, particularly in unique patient populations. We identified an increased risk of death 
and graft loss in kidney transplant recipients with evidence of high-level prescription opioid use before or 
after surgery. Transplant centers should assess opioid use in candidates being evaluated for transplant 
and reassess ongoing use after transplant. Given our findings, we believe that transplant candidates who 
receive opioids warrant careful evaluation of pain management strategies, perhaps by a multidisciplinary 
team including a pain management specialist, as well as focused monitoring of clinical status over time 
after surgery. Ongoing work is needed to develop strategies to mitigate the risk of opioid-related 
complications in this patient population. 
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FIGURE LEGENDS 
Figure 1. The incidence of death and graft failure according to prescription opioid use before and after 
kidney transplant. *p<0.05–ヰ.ヰヰヲ; ゆp=ヰ.ヰヰヱ–ヰ.ヰヰヰヲ; ょp<ヰ.ヰヰヰヱ. Le┗el ヱ, 300 mg; level 2, 301-600 mg; 
level 3, 601-1000 mg; level 4, >1000 mg per year. Abbreviations: ACGF, all-cause graft failure; DCGF, 
death-censored graft failure; ME, morphine equivalents. 
 
Figure 2. Adjusted associations of level 1-4 prescription opioid use before and after transplant with death 
and graft failure (referent=no use). Abbreviations: aHR, adjusted hazard ratio; ACGF, all-cause graft 
failure; CI, confidence interval; DCGF, death-censored graft failure.  
 























Additional Supporting Information may be found online in the supporting information tab of this article. 
 
Table S1. STROBE checklist.  
Table S2. Conversions used to standardize doses of opioid medications as morphine equivalents 
Table S3. Distributions of clinical traits of kidney transplant recipients by level of post-transplant opioid 
use 
Table S4. Propensity model for associations of baseline factors with pre- and posttransplant opioid use  
Figure S1. Relative risks of death and graft loss over the first year post-transplant, according to opioid use 
by pre-transplant period. 
Figure S2. Relative risks of death and graft loss >1 to 6 year post-transplant, according to opioid use in the 
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Table 1. Distributions of clinical traits of kidney transplant recipients by level of pre-transplant  
opioid use 
Baseline Characteristics at 











Age, years  ょ ょ ょ ょ 
   <18 6.8 3.3 2.0 1.9 2.0 
   18 to 30 7.0 9.1 9.5 9.1 8.0 
   31 to 44 17.8 21.4 22.3 22.5 22.6 
   45 to 59 35.3 36.9 37.9 37.9 42.5 
   ≥60 33.1 29.2 28.3 28.7 24.8 
Female 38.2 ヴヰ.ヲょ ヴヱ.ヰょ ヴヲ.ヶょ ヴヰ.Γょ 
Race  ょ ょ ょ ょ 
   White 52.6 52.8 53.6 54.4 56.1 
   African-American 24.8 28.2 30.3 29.9 30.2 
   Hispanic 15.1 13.1 11.7 11.3 10.6 
   Other 7.6 6.0 4.5 4.4 3.1 
Highest level of education  ょ * * ょ 
   College or higher 47.8 49.5 47.8 45.9 42.1 
   Grade/High school 42.7 42.7 43.8 45.9 49.1 
   Missing 9.6 7.9 8.4 8.2 8.8 
Employment status  ょ ょ ょ ょ 
   Working 31.5 33.1 29.2 26.8 19.6 
   Not working 54.9 55.9 61.5 63.4 70.4 
   Missing 13.6 10.9 9.3 9.8 10.1 
Health insurance type  * * ょ ょ 
   Private 37.7 39.1 35.5 32.2 25.2 
   Public 61.9 60.5 64.1 67.4 74.5 
   Missing 0.4 0.4 0.3 0.3 0.4 
Body mass index, kg/m
2
  ょ ょ ょ ょ 
   <18.5 5.0 2.7 2.7 3.3 3.5 
   18.5 to 24.9 29.2 28.5 27.6 27.2 27.8 
   25 to 30 31.7 32.0 32.1 30.4 28.3 
   >30 31.6 34.4 35.2 36.7 37.4 
   Missing 2.5 2.4 2.4 2.4 3.0 
Physical capacity status  ǂ ǂ ǂ ǂ 
   Not limited 64.8 66.2 65.4 63.6 62.5 


















   Missing 29.3 27.3 26.5 28.0 28.0 
Comorbid conditions      
   Hypertension 77.9 79.2* 78.1 79.6* 78.8 
   Diabetes mellitus 31.2 32.3* ンン.Γょ ンヵ.ンょ ンヴ.ヱょ 
   Coronary artery disease 5.4 5.7 6.3* 6.8* ヶ.Γょ 
   Cerebral vascular disease 2.2 2.2 2.3 2.9* ン.ヰょ 
   PVD 3.2 3.2 3.6 4.3 ヴ.ヵょ 
   COPD 1.0 1.3* 1.3 1.1 ヱ.Βょ 
Cause of ESRD  ょ ょ ゆ ょ 
   Hypertension 25.3 25.3 25.1 25.2 25.2 
   Diabetes mellitus 22.8 23.6 24.6 25.5 24.7 
   Glomerulonephritis 23.0 24.9 23.8 23.3 23.0 
   Polycystic kidney disease 9.9 10.0 10.3 9.6 9.9 
   Other 19.1 16.3 16.2 16.4 17.3 
Duration of dialysis, months  ょ ょ ょ ょ 
   None (pre-emptive) 21.3 16.4 11.8 10.9 8.9 
   0.1 to 24 26.9 35.9 37.9 36.0 28.1 
   25 to 60 31.3 28.1 29.0 29.8 35.0 
   >60 19.6 18.8 20.3 22.6 27.3 
   Missing 0.8 0.9 1.0 0.6 0.8 
Peak PRA level  ょ ょ ょ ょ 
   <10 70.5 68.4 66.5 66.9 65.4 
   10 to 79 17.6 19.0 19.7 20.4 19.7 
   80 6.1 7.0 7.4 7.7 9.3 
   Missing 5.7 5.7 6.5 5.0 5.5 
HLA mismatches     ょ 
   Zero A, B, DR 7.6 7.7 8.1 8.7 9.1 
   Zero DR 11.1 11.3 11.9 10.5 11.6 
   Other 81.3 81.0 80.0 80.8 79.3 
Previous organ transplant 12.6 13.9 15.3 15.4 16.7 
Era of current transplant  ょ ょ * ょ 
   2007 to 2009 20.3 19.1 17.9 19.2 18.8 
   2010 to 2012 44.9 47.1 48.7 47.8 47.8 
   2013 to 2015 34.8 33.8 33.4 33.1 33.5 
Donor type  ょ *  ょ 
   Living 36.2 39.8 38.3 35.6 31.9 


















   Deceased (ECD) 9.8 8.5 8.5 9.1 8.7 
   Deceased (DCD) 10.1 9.3 10.2 9.9 10.5 
Cold ischemia time, hours  ǂ   * 
   <12 49.8 52.1 50.6 49.3 47.7 
   13 to 24 31.3 29.9 31.6 33.6 34.7 
   25 to 36 9.3 8.7 9.2 8.7 9.8 
   >36 2.6 2.3 2.1 2.3 2.0 
   Missing 7.0 6.9 6.5 6.1 5.8 
Data presented as percentages (%) 
*p<0.05–ヰ.ヰヰヲ; ゆp=ヰ.ヰヰヱ–ヰ.ヰヰヰヲ; ょp<ヰ.ヰヰヰヱ. 
-600 mg, Level 3: 601-1000 mg, and Level 4: >1000 mg per year. 
Abbreviations: COPD, chronic obstructive pulmonary disease; DCD, donation after cardiac death; ECD, expanded 
criteria donor; ESRD, end-stage renal disease; HLA, human leukocyte antigens; PRA, panel reactive antibody; PVD, 




















Table 2. Adjusted associations of clinical factors with death and graft failure within the first year post-
transplant 
Clinical Factor Death 
Death-Censored Graft 
Failure 
All-Cause Graft Failure 
Pre-transplant opioid use    
   No use Reference Reference Reference 
   Level 1 0.95 (0.84-1.07) 1.03 (0.92-1.14) 1.00 (0.92-1.09) 
   Level 2 1.12 (0.93-1.34) 1.06 (0.90-1.24) 1.11 (0.98-1.26) 
   Level 3 1.24 (0.99-1.55) 1.02 (0.82-1.28) 1.11 (0.95-1.31) 
   Level 4 1.46 (1.28-1.66)ょ 1.15 (1.01-1.30)* 1.28 (1.17-1.41)ょ 
Age, years    
   <18 0.87 (0.44-1.72) 1.23 (0.79-1.92) 1.23 (0.86-1.77) 
   18 to 30 Reference Reference Reference 
   31 to 44 1.52 (1.08-2.15)* 0.83 (0.69-0.99)* 0.94 (0.80-1.10) 
   45 to 60 2.27 (1.61-3.19)ょ 0.72 (0.60-0.87)ゆ 0.98 (0.83-1.15) 
   ≥60 4.22 (2.78-6.42)ょ 0.67 (0.51-0.89)* 1.25 (0.99-1.57) 
Female 0.88 (0.79-0.98)* 1.10 (1.00-1.20) 1.00 (0.93-1.08) 
Race    
   White Reference Reference Reference 
   African American 0.85 (0.76-0.96)* 1.07 (0.96-1.19) 0.99 (0.92-1.08) 
   Hispanic 0.69 (0.55-0.86)* 0.76 (0.62-0.91)* 0.73 (0.63-0.85)ょ 
   Other 0.71 (0.52-0.96)* 0.76 (0.58-0.99)* 0.75 (0.61-0.92)* 
Highest level of education    
   College or higher Reference Reference Reference 
   Grade/high school 0.87 (0.78-0.98)* 0.96 (0.87-1.06) 0.92 (0.85-0.99)* 
   Missing 1.10 (0.93-1.29) 0.87 (0.75-1.02) 0.98 (0.87-1.10) 
Employment status    
   Working 0.77 (0.64-0.91)* 0.82 (0.71-0.95)* 0.80 (0.72-ヰ.Γヰ)ゆ 
   Not working Reference Reference Reference 
   Missing 0.91 (0.75-1.09) 0.89 (0.75-1.04) 0.89 (0.79-1.01) 
Health insurance type    
   Private Reference Reference Reference 
   Public 0.83 (0.73-0.95)* 0.99 (0.88-1.11) 0.92 (0.84-1.00) 
   Missing 0.00 (0-6.82x10
63
) 0.18 (0.03-1.28) 0.11 (0.02-0.81)* 
Body mass index, kg/m
2
    
   <18.5 1.22 (0.87-1.70) 0.93 (0.72-1.20) 0.98 (0.80-1.20) 
   18.5 to 24.9 Reference Reference Reference 
   25 to 30 0.94 (0.83-1.06) 1.22 (1.09-ヱ.ンΑ)ゆ 1.08 (0.99-1.18) 
   >30 0.95 (0.83-1.08) 1.41 (1.26-ヱ.ヵΒ)ょ 1.18 (1.08-ヱ.ヲΓ)ゆ 
   Missing 1.50 (1.17-1.94)* 1.19 (0.91-1.55) 1.31 (1.08-1.59)* 
Physical capacity status    
   Not limited Reference Reference Reference 
   Limited 1.55 (1.31-ヱ.Βン)ょ 1.12 (0.94-1.33) 1.31 (1.16-ヱ.ヴΒ)ょ 
   Missing 1.22 (1.09-ヱ.ンヶ)ゆ 1.11 (1.00-1.22)* 1.14 (1.05-1.23)* 
Comorbid conditions    


















   Diabetes mellitus 1.38 (1.18-ヱ.ヶヲ)ょ 0.90 (0.77-1.06) 1.10 (0.98-1.23) 
   Coronary artery disease 1.34 (1.14-ヱ.ヵΑ)ゆ 1.11 (0.93-1.32) 1.23 (1.09-ヱ.ンΓ)ゆ 
   Cerebral vascular disease 1.12 (0.89-1.41) 1.07 (0.83-1.38) 1.10 (0.93-1.32) 
   PVD 1.41 (1.18-ヱ.ヶΑ)ゆ 1.12 (0.91-1.39) 1.30 (1.13-ヱ.ヵヰ)ゆ 
   COPD 1.75 (1.30-ヲ.ンヴ)ゆ 1.58 (1.15-2.19)* 1.67 (1.34-ヲ.ヰヱ)ょ 
Cause of ESRD    
   Hypertension 1.30 (1.10-1.53)* 0.95 (0.83-1.08) 1.04 (0.94-1.16) 
   Diabetes mellitus 1.34 (1.10-1.63)* 0.99 (0.82-1.20) 1.10 (0.96-1.27) 
   Glomerulonephritis Reference Reference Reference 
   Polycystic kidney disease 0.92 (0.73-1.16) 0.72 (0.60-ヰ.ΒΑ)ゆ 0.78 (0.67-0.90)ゆ 
   Other 1.26 (1.05-1.52)* 1.02 (0.90-1.17) 1.07 (0.96-1.20) 
Duration of dialysis, 
months 
   
   None (pre-emptive) 0.70 (0.58-ヰ.Βヵ)ゆ 0.70 (0.60-ヰ.Βン)ょ 0.71 (0.63-ヰ.Βヱ)ょ 
   0.1 to 24 Reference Reference Reference 
   25 to 60 1.23 (1.08-1.40)* 1.11 (0.99-1.25) 1.16 (1.06-1.27)* 
   >60 1.74 (1.51-ヲ.ヰヱ)ょ 1.46 (1.28-ヱ.ヶヶ)ょ 1.55 (1.40-ヱ.Αヱ)ょ 
   Missing 1.22 (0.73-2.04) 5.16 (4.06-ヶ.ヵΑ)ょ 3.54 (2.83-ヴ.ヴヲ)ょ 
Peak PRA level    
   <10 Reference Reference Reference 
   10 to 79 1.08 (0.95-1.22) 1.04 (0.93-1.17) 1.05 (0.97-1.15) 
   80 1.26 (1.04-1.52)* 1.25 (1.06-1.47)* 1.21 (1.06-1.37)* 
   Missing 0.96 (0.76-1.20) 1.01 (0.82-1.24) 0.97 (0.83-1.14) 
HLA mismatches    
   Zero A, B, DR 0.89 (0.74-1.08) 0.76 (0.64-0.91)* 0.82 (0.71-0.93)* 
   Zero DR 0.98 (0.84-1.14) 0.91 (0.79-1.04) 0.95 (0.85-1.05) 
   Other Reference Reference Reference 
Previous organ transplant 1.22 (1.05-1.42)* 1.20 (1.05-1.36)* 1.22 (1.10-ヱ.ンヵ)ゆ 
Era of current transplant    
   2007 to 2009 Reference Reference Reference 
   2010 to 2012 0.92 (0.80-1.05) 0.87 (0.78-0.98)* 0.89 (0.81-0.97)* 
   2013 to 2015 0.90 (0.78-1.03) 0.73 (0.65-ヰ.Βン)ょ 0.80 (0.73-ヰ.ΒΒ)ょ 
Donor type    
   Living 0.83 (0.71-0.97)* 0.78 (0.68-ヰ.Γヰ)ゆ 0.81 (0.73-ヰ.Γヰ)ゆ 
   Deceased (SCD) Reference Reference Reference 
   Deceased (ECD) 1.36 (1.19-ヱ.ヵヴ)ょ 2.16 (1.92-ヲ.ヴン)ょ 1.67 (1.53-ヱ.Βン)ょ 
   Deceased (DCD) 1.11 (0.96-1.28) 1.37 (1.20-ヱ.ヵヵ)ょ 1.26 (1.14-ヱ.ンΓ)ょ 
Cold ischemia time, hours    
   <12 Reference Reference Reference 
   13 to 24 1.09 (0.97-1.23) 1.27 (1.14-ヱ.ヴヲ)ょ 1.20 (1.10-ヱ.ンヱ)ょ 
   25 to 36 1.27 (1.09-1.49)* 1.63 (1.42-ヱ.ΒΒ)ょ 1.48 (1.33-ヱ.ヶヶ)ょ 
   >36 1.45 (1.12-1.86)* 1.75 (1.40-ヲ.ヱΒ)ょ 1.61 (1.35-ヱ.Γヱ)ょ 
   Missing 1.01 (0.79-1.27) 1.05 (0.85-1.30) 1.02 (0.87-1.20) 
Data presented as aHR (95% CI). 
*p<0.05–ヰ.ヰヰヲ; ゆp=ヰ.ヰヰヱ–ヰ.ヰヰヰヲ; ょp<ヰ.ヰヰヰヱ. 
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary 


















disease; HLA, human leukocyte antigens; PRA, panel reactive antibody; PVD, peripheral vascular disease; 




















Table 3. Adjusted associations of clinical factors with death and graft failure within the first and second post-
transplant years 
Clinical Factor Death 
Death-Censored Graft 
Failure 
All-Cause Graft Failure 
Posttransplant opioid use    
   No use Reference Reference Reference 
   Level 1 1.09 (0.93-1.27) 1.05 (0.91-1.21) 1.07 (0.96-1.20) 
   Level 2 1.36 (1.14-ヱ.ヶヴ)ゆ 1.20 (1.01-1.43)* 1.27 (1.11-ヱ.ヴヵ)ゆ 
   Level 3 1.77 (1.41-ヲ.ヲヱ)ょ 1.36 (1.08-1.71)* 1.53 (1.29-ヱ.Βヱ)ょ 
   Level 4 2.24 (1.93-ヲ.ヶヰ)ょ 1.35 (1.15-ヱ.ヵΓ)ゆ 1.68 (1.50-ヱ.ΒΓ)ょ 
Age, years    
   <18 0.41 (0.18-0.93)* 0.91 (0.55-1.53) 0.79 (0.53-1.20) 
   18 to 30 Reference Reference Reference 
   31 to 44 1.11 (0.77-1.60) 0.55 (0.45-ヰ.ヶヶ)ょ 0.63 (0.53-ヰ.Αヵ)ょ 
   45 to 59 1.89 (1.34-ヲ.ヶヵ)ゆ 0.33 (0.27-ヰ.ヴヰ)ょ 0.55 (0.47-ヰ.ヶヵ)ょ 
   ≥60 3.18 (2.01-ヵ.ヰヴ)ょ 0.23 (0.17-ヰ.ンン)ょ 0.62 (0.48-ヰ.Βヲ)ゆ 
Female 0.86 (0.75-0.98)* 1.00 (0.89-1.13) 0.93 (0.85-1.03) 
Race    
   White Reference Reference Reference 
   African American 0.76 (0.66-ヰ.ΒΓ)ゆ 1.54 (1.35-ヱ.ΑΑ)ょ 1.16 (1.04-1.28)* 
   Hispanic 0.51 (0.37-ヰ.Αヰ)ょ 0.63 (0.48-0.84)* 0.57 (0.46-ヰ.Αヱ)ょ 
   Other 0.58 (0.41-0.83)* 0.81 (0.57-1.13) 0.66 (0.51-0.86)* 
Highest level of education    
   College or higher Reference Reference Reference 
   Grade/high school 1.06 (0.93-1.21) 1.12 (0.98-1.27) 1.11 (1.01-1.23)* 
   Missing 0.91 (0.74-1.13) 1.10 (0.91-1.34) 1.02 (0.88-1.19) 
Employment status    
   Working 0.66 (0.53-ヰ.Βヲ)ゆ 0.72 (0.59-ヰ.ΒΑ)ゆ 0.70 (0.61-ヰ.Βヲ)ょ 
   Not working Reference Reference Reference 
   Missing 0.86 (0.69-1.08) 0.73 (0.58-0.92)* 0.80 (0.67-0.94)* 
Health insurance type    
   Private Reference Reference Reference 
   Public 0.93 (0.79-1.09) 0.89 (0.76-1.04) 0.90 (0.80-1.01) 
   Missing 0.00 (0-4.76x10
93
) 0.54 (0.08-3.93) 0.34 (0.05-2.40) 
Body mass index, kg/m
2
    
   <18.5 1.34 (0.94-1.92) 0.84 (0.63-1.14) 0.97 (0.76-1.23) 
   18.5 to 24.9 Reference Reference Reference 
   25 to 30 0.82 (0.71-0.95)* 1.07 (0.92-1.25) 0.95 (0.85-1.06) 
   >30 0.84 (0.71-1.00)* 1.27 (1.08-1.49)* 1.06 (0.94-1.20) 
   Missing 0.69 (0.46-1.05) 0.75 (0.50-1.13) 0.73 (0.54-0.99)* 
Physical capacity status    
   Not limited Reference Reference Reference 
   Limited 0.99 (0.81-1.22) 1.35 (1.10-1.66)* 1.15 (0.99-1.35) 
   Missing 1.02 (0.90-1.17) 0.96 (0.84-1.10) 0.99 (0.90-1.10) 


















   Hypertension 0.93 (0.80-1.10) 0.94 (0.81-1.10) 0.95 (0.84-1.07) 
   Diabetes mellitus 1.45 (1.21-ヱ.Αヴ)ょ 1.03 (0.84-1.27) 1.26 (1.10-1.45)* 
   Coronary artery disease 1.23 (1.03-1.47)* 1.15 (0.91-1.44) 1.20 (1.04-1.40)* 
   Cerebral vascular disease 1.16 (0.88-1.53) 0.92 (0.63-1.34) 1.04 (0.82-1.32) 
   PVD 1.51 (1.23-ヱ.Βヶ)ょ 1.20 (0.88-1.62) 1.32 (1.10-1.59)* 
   COPD 1.57 (1.09-2.26)* 1.08 (0.62-1.87) 1.54 (1.13-2.11)* 
Cause of ESRD    
   Hypertension 1.31 (1.07-1.59)* 1.04 (0.88-1.23) 1.13 (0.99-1.29) 
   Diabetes mellitus 1.21 (0.95-1.54) 0.79 (0.61-1.02) 0.93 (0.78-1.11) 
   Glomerulonephritis Reference Reference Reference 
   Polycystic kidney disease 0.87 (0.66-1.14) 0.77 (0.59-1.00) 0.82 (0.68-1.00)* 
   Other 1.20 (0.97-1.48) 0.82 (0.68-0.98)* 0.91 (0.79-1.05) 
Duration of dialysis, months    
   None (pre-emptive) 0.68 (0.54-ヰ.Βヵ)ゆ 0.66 (0.53-ヰ.Βン)ゆ 0.68 (0.58-ヰ.Βヰ)ょ 
   0.1 to 24 Reference Reference Reference 
   25 to 60 1.19 (1.02-1.39)* 1.10 (0.94-1.28) 1.13 (1.01-1.27)* 
   >60 1.62 (1.36-ヱ.Γン)ょ 1.10 (0.92-1.31) 1.28 (1.13-ヱ.ヴヶ)ゆ 
   Missing 1.42 (0.81-2.47) 0.94 (0.48-1.81) 1.22 (0.78-1.90) 
Peak PRA level    
   <10 Reference Reference Reference 
   10 to 79 1.02 (0.88-1.19) 1.10 (0.95-1.28) 1.05 (0.94-1.18) 
   80 0.98 (0.77-1.26) 1.01 (0.79-1.29) 0.98 (0.81-1.18) 
   Missing 1.00 (0.72-1.38) 1.17 (0.84-1.62) 1.11 (0.88-1.41) 
HLA mismatches    
   Zero A, B, DR 1.10 (0.90-1.35) 0.61 (0.47-ヰ.ΑΓ)ゆ 0.87 (0.74-1.03) 
   Zero DR 0.77 (0.63-0.94)* 0.82 (0.68-1.00)* 0.83 (0.72-0.96)* 
   Other Reference Reference Reference 
Previous organ transplant 1.51 (1.27-ヱ.ΑΓ)ょ 1.13 (0.94-1.35) 1.28 (1.12-ヱ.ヴヵ)ゆ 
Era of current transplant    
   2007 to 2009 Reference Reference Reference 
   2010 to 2012 0.90 (0.80-1.02) 0.84 (0.75-0.95)* 0.88 (0.80-0.96)* 
   2013 to 2015 1.02 (0.83-1.24) 0.68 (0.55-ヰ.Βヵ)ゆ 0.86 (0.73-1.00)* 
Donor type    
   Living 0.86 (0.71-1.04) 0.71 (0.60-ヰ.Βヵ)ゆ 0.75 (0.65-ヰ.Βヵ)ょ 
   Deceased (SCD) Reference Reference Reference 
   Deceased (ECD) 1.48 (1.27-ヱ.Αン)ょ 1.92 (1.62-ヲ.ヲΒ)ょ 1.56 (1.38-ヱ.Αヶ)ょ 
   Deceased (DCD) 1.24 (1.04-1.49)* 0.84 (0.68-1.03) 1.04 (0.90-1.20) 
Cold ischemia time, hours    
   <12 Reference Reference Reference 
   13 to 24 1.11 (0.96-1.29) 1.14 (0.99-1.33) 1.10 (0.99-1.23) 
   25 to 36 1.12 (0.92-1.37) 1.21 (0.99-1.48) 1.15 (0.99-1.34) 
   >36 1.29 (0.93-1.78) 1.43 (1.05-1.95)* 1.33 (1.05-1.69)* 
   Missing 0.98 (0.75-1.28) 1.21 (0.96-1.53) 1.14 (0.95-1.37) 
Data presented as aHR (95% CI). 


















Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary 
disease; DCD, donation after cardiac death; ECD, expanded criteria donor; ESRD, end-stage renal disease; 
HLA, human leukocyte antigens; PRA, panel reactive antibody; PVD, peripheral vascular disease; SCD, 





















Figure 1. The incidence of death and graft failure according to prescription opioid use before and after kidney 
transplant. *p<0.05–ヰ.ヰヰヲ; ゆp=ヰ.ヰヰヱ–ヰ.ヰヰヰヲ; ょp<0.0001. Level 1, 300 mg; level 2, 301-600 mg; level 3, 601-1000 
mg; level 4, >1000 mg per year. Abbreviations: ACGF, all-cause graft failure; DCGF, death-censored graft failure; 
ME, morphine equivalents. 
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Figure 2. Adjusted associations of level 1-4 prescription opioid use before and after transplant with death and 
graft failure (referent=no use). Abbreviations: aHR, adjusted hazard ratio; ACGF, all-cause graft failure; CI, 
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Relative Risks of Death and Graft Loss >1 to 2 Year Post-Transplant,
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